The current STATe of biomarkers to predict the response to anti-angiogenic therapies.
Tran
Phuoc T
PT
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305-5151, USA.
Felsher
Dean W
DW
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D050796:STAT3 Transcription Factor / Q000187:drug effects / Q000502:physiology; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000187:drug effects / Q000502:physiology*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D050796:STAT3 Transcription Factor; C494086:STAT3 protein, human; D000068258:Bevacizumab; D040301:Vascular Endothelial Growth Factor Receptor-2